Get the Stockscreener App
0.1686
6.33%
-0.0114
After Hours:
.17
0.0014
+0.83%
Oragenics Inc stock is traded at $0.1686, with a volume of 358.66K.
It is down -6.33% in the last 24 hours and down -11.26% over the past month.
Oragenics, Inc. focuses on developing antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its product candidates also comprise LPT3-04, a naturally occurring dietary substance for weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay. Oragenics, Inc. has collaboration agreements with Intrexon Corporation and its subsidiary, Intrexon Actobiotics NV to develop AG013 as a potential treatment of oral mucositis for cancer patients. It also has license agreements with LPThera LLC to develop LPT3-04, a weight-loss product candidate; and Texas A&M University System for access to new homologs of the lantibiotic Mutacin 1140 (MU1140) and other lantibiotics, as well as holds licenses from the University of Florida Research Foundation, Inc. for MU1140 product candidates. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.
See More
Previous Close:
$0.18
Open:
$0.18
24h Volume:
358.66K
Relative Volume:
0.08
Market Cap:
$4.19M
Revenue:
-
Net Income/Loss:
$-20.26M
P/E Ratio:
-0.0197
EPS:
-8.54
Net Cash Flow:
$-8.25M
1W Performance:
-13.49%
1M Performance:
-11.26%
6M Performance:
-56.21%
1Y Performance:
-87.78%
1-Day Range:
$0.1653
$0.1859
1-Week Range:
$0.1648
$0.19
52-Week Range:
$0.1617
$3.43
Oragenics Inc Stock (OGEN) Company Profile
Name
Oragenics Inc
Sector
Industry
Phone
813-286-7900
Address
4902 Eisenhower Boulevard, Suite 125, Tampa, FL
Compare OGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OGEN
Oragenics Inc
|
0.1686 | 4.19M | 0 | -20.26M | -8.25M | -8.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Oragenics Inc Stock (OGEN) Latest News
Oragenics: Q1 Earnings Snapshot - New Haven Register
Oragenics (NYSE:OGEN) Now Covered by StockNews.com - Defense World
Oragenics Appoints New CEO and Amends Employment Terms By Investing.com - Investing.com Nigeria
Oragenics Appoints New CEO and Amends Employment Terms - Investing.com Australia
Oragenics Appoints Janet Huffman as CEO and CFO - TipRanks
StockNews.com Initiates Coverage on Oragenics (NYSE:OGEN) - Defense World
Oragenics, Inc. to Participate at the 15th Annual Traumatic Brai - GuruFocus
Oragenics, Inc. to Participate at the 15th Annual Traumatic Brain Injury Conference | OGEN Stock News - GuruFocus
Oragenics, Inc. to Present at the 15th Annual Traumatic Brain Injury Conference on Advances in mTBI Detection and Management - Nasdaq
Oragenics, Inc. to Participate at the 15th Annual Traumatic Brain Injury Conference - GlobeNewswire
Oragenics (NYSE:OGEN) Now Covered by Analysts at StockNews.com - Defense World
Oragenics, Inc. Announces Health and Disability Ethics Committee - GuruFocus
Oragenics, Inc. Announces Health and Disability Ethics Committee Submission for Phase IIa Concussion Trial - The Manila Times
Oragenics Announces Health And Disability Ethics Committee Submission - MarketScreener
Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit - GlobeNewswire
Oragenics gears up for Phase II trials, appoints new CEO - MSN
Oragenics (NYSE:OGEN) Coverage Initiated at StockNews.com - Defense World
OGEN stock touches 52-week low at $0.19 amid sharp annual decline By Investing.com - Investing.com South Africa
OGEN stock touches 52-week low at $0.19 amid sharp annual decline - Investing.com
OGEN stock touches 52-week low at $0.24 amid sharp annual decline - Investing.com Australia
Oragenics reports progress in concussion drug development By Investing.com - Investing.com South Africa
OGEN stock touches 52-week low at $0.24 amid sharp annual decline By Investing.com - Investing.com South Africa
Oragenics reports progress in concussion drug development - Investing.com
Oragenics Provides Q1 2025 Shareholder Update On Strategic And Financial Progress - MarketScreener
Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress - The Manila Times
Oragenics (NYSE:OGEN) Coverage Initiated by Analysts at StockNews.com - Defense World
Investornewsbreaks Oragenics Inc. Files 2024 Annual Report, Addresses Going Concern Status - MENAFN.COM
CEMATRIX To Report Fourth Quarter and 2024 Year End Results on March 26, 2025 - The Manila Times
Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K - TradingView
Oragenics, Inc. Files Annual Report for 2024, Receives Unqualified Audit Opinion - Nasdaq
Going Concern Alert: Oragenics Brain Treatment Pipeline Faces Critical Financial Test - StockTitan
OGEN Stock Plummets to 52-Week Low of $0.25 Amid Market Struggles - Investing.com Australia
OGEN Stock Plummets to 52-Week Low of $0.25 Amid Market Struggles By Investing.com - Investing.com South Africa
Oragenics Inc Stock (OGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):